AB0847 COMORBIDITIES IN IDIOPATHIC INFLAMMATORY MYOPATHIES: DATA FROM THE MYOCITE COHORT

• Published in: Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 1636 - 1637
• Main Authors: Conticini, E, Khursheed, T, Anuja, A K, Agarwal, V, Gupta, L
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 01.06.2023
• Subjects: Age; Antibodies; Autoantibodies; Cancer; Cardiovascular diseases; Comorbidity; Connective tissue diseases; Dermatomyositis; Diabetes mellitus; Disease; Epidemiology; Infections; Inflammation; Inflammatory diseases; Mixed connective tissue disease; Musculoskeletal diseases; Myositis; Polymyositis; Population studies; Statistical analysis; Thyroiditis; tRNA
• ISSN: 0003-4967; 1468-2060
• DOI: 10.1136/annrheumdis-2023-eular.6031

BackgroundPatients affected by idiopathic inflammatory myopathies (IIM) may suffer from comorbidities such as cancer and cardiovascular diseases, calling for optimized evaluation and additional management(1, 2).ObjectivesWe aimed to explore the prevalence and profile of comorbidities in a cohort of Indian patients diagnosed with IIM, and to explore their association with a disease subtype and autoantibodies.MethodsInformation on demographics, disease subtype and autoantibodies in Indian patients with IIM were extracted from the MyoCite dataset. Comorbidities were classified as autoimmune, cardiovascular, cancer, infections, Diabetes Mellitus and others.Pearson’s chi-square and Fisher’s exact test were used to assess differences in the occurrence of any comorbidity between the various IIM subtypes and antibodies.ResultsOf 250 patients (F:M 3.9:1, median age 36.0 ± 15.4), the majority (110, 44.0%) were diagnosed with dermatomyositis (DM), followed by overlap myositis (OM) (59, 23.6%) and anti-synthetase syndrome (ASS) (45, 18.0%). Patients with comorbidities had a higher median age (40 ± 13.9 years) compared to patients without comorbidities (35 ± 16 years) without any statistical significance. A statistically significant increase (P<0.001) in female to male ratio was observed in patients with comorbidities (10.5:1) compared to patients without comorbidities (2.3:1). Female gender was associated with higher odds of any comorbidity (OR = 4.58; 95 CI = 2.17-9.65).Comorbidities were identified in nearly half (115, 46.0%) of the patients, with autoimmune comorbidities being the most common (72/115, 62.6%) followed by cardiovascular (38/115, 33.0%) and infections (24/115, 20.9%). Hypertension was identified as the most common comorbidity (38/115 33.0%) overall, followed by thyroiditis (26/115, 22.6%) and mixed connective tissue disease (23/115, 20.0%). Statistically significant differences (P<0.001) in frequency of comorbidities was observed in DM (OR = 0.21; 95 CI = 0.12-0.36) and OM (OR = 136.3; 95 CI = 18.44-1008.45).ConclusionDespite younger population with IIM, comorbidities are frequently reported in nearly half of Indian patients with IIM. It is noteworthy that autoimmune comorbidities and infections are fairly common with substantial cardiovascular risk calling for optimized assessment and care.References[1]Pawlitzki M, Acar L, Masanneck L, Willison A, Regner-Nelke L, Nelke C, et al. Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019. Neurological research and practice. 2022;4(1):62.[2]Lee JS, Kim MJ, Lee HY, Ahn SY, Song YW, Lee EB, et al. AB0603 Major Comorbidities of Idiopathic Inflammatory Myositis Affecting Survival and Functional Impairment: A Population-Based Study Using 11 Years of Follow Up from The National Health Insurance in Korea. 2016;75(Suppl 2):1111.Table 1: Comparison of patients with comorbidities and without comorbidities in the Myocite cohortParameterPatients with comorbidities (n=115)Patients without comorbidities (n=135)P-ValueMedian age (years)40 ± 13.935 ± 160.217Female105 (91.3%)94 (69.6%)<0.001Male10 (8.7%)41(30.4%)<0.001Disease SubtypeDermatomyositis 110/250 (44.0%)28 (24.3%)82 (60.7%)<0.001Overlap Myositis 59/250 (23.6%)58 (50.5%)1 (0.7%)<0.001Antisynthetase syndrome 45/250 (18.0%)17 (14.8%)28 (20.7%)0.222Juvenile Dermatomyositis 33/250 (13.2%)7 (6.1%)26 (19.3%)0.002Polymyositis 27/250 (10.8%)7 (6.1%)20 (14.8%)0.027Cancer-Associated Myositis 9/250 (3.6%)7 (6.1%)2 (1.5%)0.085Juvenile Overlap Myositis 3/250 (1.2%)3 (2.6%)00.096Necrotizing Autoimmune Myositis 3/250 (1.2%)03 (2.2%)0.252Clinically Amyopathic Dermatomyositis 1/250 (0.4%)01 (0.7%)1.000AntibodiesAnti-Nuclear Antibodies 173/250 (69.2%)84 (73.0%)89 (65.9%)0.224Myositis-Specific Antibodies 93/250 (37.2%)33 (28.7%)60 (44.4%)0.010Myositis-Associated Antibodies 86/250 (34.4%)40 (34.8%)46 (34.1%)0.906Anti-Aminoacyl tRNA Synthetase Antibodies 33/250 (13.2%)12 (10.4%)21 (15.6%)0.233Acknowledgements:NIL.Disclosure of InterestsNone Declared.